Shanghai Ark Bio and Partex Collaborate on ATR Inhibitor AK0658 Development
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based...
Bayer Files for Approval of Gadoquatrane MRI Contrast Agent in Japan
German pharmaceutical giant Bayer AG (ETR: BAYN) this week filed a marketing application with Japan’s...
MicroPort CardioFlow to Acquire 49% Stake in La Ronda for RMB 171 Million
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
MSD Appoints Kyle Tattle as President of China Operations
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced leadership changes in its China and...
Zelgen’s Jaktinib Receives NMPA Approval for Myelofibrosis Treatment
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received marketing approval from...
MSD and Daiichi Sankyo Withdraw US Filing for Patritumab Deruxtecan in EGFR-Mutated NSCLC
Partners Merck, Sharp & Dohme (MSD; NYSE: MRK) and Daiichi Sankyo (TYO: 4568) announced the...
Fosun Pharma’s FCN-159 and FCN-437c Win NMPA Marketing Approvals
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced the receipt of marketing...
CSPC Pharmaceutical in Advanced Talks for $5B Licensing Deals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) revealed that it is currently in negotiations with...
Acotec Scientific’s E-Peridge Balloon Catheter Approved by China’s NMPA
China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...
Jiangsu Hengrui Secures NMPA Approvals for Trastuzumab Rezetecan, Famitinib and HR20013
China’s Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received separate marketing...
NMPA Approves Mabwell’s 8MW0511 for Febrile Neutropenia Prevention
China’s National Medical Products Administration (NMPA) has approved Mabwell (Shanghai) Bioscience Co., Ltd’s (SHA: 688062)...
Hinova’s Deutenzalutamide Approved for Metastatic Prostate Cancer in China
Chengdu-based biotech Hinova Pharmaceuticals Inc. (SHA: 688302) announced that the New Drug Application (NDA) for...
Sino Biopharmaceutical’s TQB2868 Shows Strong Results in Phase II Pancreatic Cancer Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented data from its Phase II clinical trial (TQB2868-ALTN-II-01)...
Hansoh Pharma Gains NMPA Clinical Approvals for HS-10510, HS-10542, and HS-20118
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that it has received separate clinical...
Genor Biopharma Gains NMPA Approval for CDK4/6 Inhibitor Lerociclib in China
China’s Genor Biopharma Co., Ltd (HKG: 6998) announced that it has received marketing clearance from...
Astellas Pharma Licenses Evopoint’s CLDN18.2 ADC for Global Development
Japan-based Astellas Pharma Inc. (TYO: 4503) has entered into a licensing agreement with China-headquartered Evopoint...
Danaher Partners with AstraZeneca to Advance Precision Medicine
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced a strategic partnership with...
Innovent Biologics Doses First Patient in Phase III Psoriasis Trial for Picankibart
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first subject dosing in a Phase III...
GSK Halts PIVOT-PO Trial Early as Tebipenem HBr Meets Efficacy Targets for cUTI
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced the early termination of the pivotal Phase...
Amoytop Biotech Wins NMPA Approval for Weekly Inpegsomatropin in Pediatric Growth Deficiency
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) announced that it has received marketing approval from...